Media stories about Uroplasty (NASDAQ:UPI) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Uroplasty earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 45.2263274617841 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Uroplasty (UPI) remained flat at $$1.22 during midday trading on Wednesday. Uroplasty has a twelve month low of $1.05 and a twelve month high of $4.05. The firm has a market cap of $27.68, a P/E ratio of -4.07 and a beta of -1.26.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Uroplasty (UPI) Stock Price” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-uroplasty-upi-stock-price.html.
Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.